Quantcast
Home / News / Merck settles Vytorin shareholder class-action suit

Merck settles Vytorin shareholder class-action suit

Merck will pay $5.1 million in attorney fees and institute corporate reforms under the terms of a settlement of a shareholder class action concerning the alleged suppression of negative clinical test results for the blockbuster anti-cholesterol drug Vytorin.

Leave a Reply

Your email address will not be published. Required fields are marked *

*